TY - JOUR
T1 - Kronisk bihulebetændelse og type 2-sygdom
AU - Aanæs, Kasper
AU - Alanin, Mikkel Christian
AU - Arndal, Elisabeth
AU - Backer, Vibeke
AU - Kiær, Eva Kirkegaard
AU - Rubek, Niclas
AU - Sørensen, Henrik Bredahl
AU - von Buchwald, Christian
PY - 2022/3/7
Y1 - 2022/3/7
N2 - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.
AB - Diseases of the upper and lower airways are commonly described as global airway disease, which shares basic inflammatory mechanisms, and airway comobidity is frequently found. The prevalence of chronic rhinosinusitis (CRS) is 5-12%, characterised as CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP). Inflammation in CRSwNP is often type 2, whereas CRSsNP often involves non-type 2. New monoclonal antibodies towards type-2 inflammation have been launched internationally to treat refractory severe CRSwNP, with effect on polyps, congestions and smell, as well as quality of life. This review gives a summary of the current treatment modalities.
KW - Chronic Disease
KW - Humans
KW - Nasal Polyps/complications
KW - Quality of Life
KW - Rhinitis/complications
KW - Sinusitis/complications
M3 - Review
C2 - 35315753
SN - 0041-5782
VL - 184
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
IS - 10
ER -